Edesa Biotech Reports $2.2 Million Net Loss and Increases Cash Reserves to $12.1 Million

Edesa Biotech, Inc. reported a net loss of $2.2 million for the three months ending December 31, 2025, translating to a loss of $0.28 per common share. This represents an increase in net loss compared to the $1.6 million loss, or $0.48 per share, reported for the same period in 2024. The company's total operating expenses rose to $2.3 million, up from $1.9 million year-over-year, primarily driven by increased research and development (R&D) and general administrative expenses. R&D expenses increased to $1.1 million from $1.0 million, attributed to preparations for a planned Phase 2 clinical study of EB06, a treatment for vitiligo.

In terms of financial position, Edesa's cash and cash equivalents increased to $12.1 million as of December 31, 2025, compared to $10.8 million at the end of the previous quarter. The company also reported a working capital surplus of $12.0 million, up from approximately $10.4 million. The increase in cash was bolstered by net proceeds of approximately $3.4 million from the sale of common shares under an At The Market (ATM) offering agreement, which allowed the company to sell shares periodically. This was a significant increase from the $0.6 million raised through the same mechanism in the prior year.

Edesa has made strategic moves to enhance its capital structure, including the issuance of 834 Series B-1 Preferred Shares and 3,468,746 common shares in a private placement that generated approximately $15.0 million in gross proceeds. The company also entered into a multi-year contribution agreement with the Canadian government, securing up to C$23 million in funding for its Phase 3 clinical study of EB05, which is aimed at treating Acute Respiratory Distress Syndrome (ARDS). This funding includes a non-repayable portion of C$5.8 million, with the remainder being conditionally repayable starting in 2032.

Operationally, Edesa is focused on advancing its clinical pipeline, which includes EB06 for vitiligo and EB05 for ARDS. The company has received regulatory approval from Health Canada to conduct a Phase 2 study of EB06 and is in discussions with the U.S. FDA regarding the same. The company’s employee headcount remains stable, with no significant changes reported in staffing levels. Edesa's management anticipates that the current cash reserves, along with future sales from the ATM offering and grant reimbursements, may not be sufficient to fund operations through the end of fiscal 2026, prompting plans to seek additional financing.

Looking ahead, Edesa Biotech is committed to continuing its R&D efforts and exploring strategic partnerships to enhance its product pipeline. The company acknowledges the need for additional funding to support its operations and clinical trials, which may involve equity sales, government grants, or other financing arrangements. The management's outlook remains cautious, emphasizing the importance of securing adequate capital to sustain its development initiatives and operational needs.